IP Library Granted Patent US 11,976,323
Granted Patent B2
US 11,976,323 · App. 16/736,071 · Granted May 7, 2024

Method of nucleic acid sequence determination

Inventors: Kandaswamy Vijayan (San Diego, CA); Pinar Iyidogan (San Diego, CA)
Assignee: PACIFIC BIOSCIENCES OF CALIFORNIA, INC.
C12Q1/6869C12N9/1247C12Q1/6874C12Y207/07006
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,976,323
App. No.
16/736,071
Granted
May 7, 2024
Kind
B2
Abstract

Provided are sequencing-by-binding methods of detecting cognate nucleotides using a crippled DNA polymerizing enzyme that possesses the ability to bind the next correct nucleotide downstream of a primer in a template-dependent fashion, but does not possess the activity needed to promote phosphodiester bond formation. Use of the crippled DNA polymerase permits interrogation of one nucleotide at a time, without incorporation of any nucleotide. Labeled nucleotides, such as fluorescently labeled nucleotides, can be used in conjunction with the crippled DNA polymerase to establish cognate nucleotide identity in a rapid manner.

Claims (11)

1. A mutant DNA polymerase comprising a polypeptide sequence, said polypeptide sequence comprising SEQ ID NO:12,

wherein said mutant DNA polymerase forms ternary complexes with primed template nucleic acid molecules and cognate nucleotides, and

wherein said mutant DNA polymerase is incapable of magnesium-catalyzed phosphodiester bond formation.

2. The mutant DNA polymerase of claim 1 , wherein the mutant DNA polymerase catalyzes formation of phosphodiester bonds in the presence of manganese ions.

3. The mutant DNA polymerase of claim 1 , wherein the polypeptide sequence of the mutant DNA polymerase comprises SEQ ID NO:1 with the exception of comprising SEQ ID NO:12 and having glutamate at amino acid position 381.

4. The mutant DNA polymerase of claim 1 , wherein the polypeptide sequence of the mutant DNA polymerase comprises SEQ ID NO:2 with the exception of comprising SEQ ID NO:12 and having glutamate at amino acid position 364.

5. The mutant DNA polymerase of claim 1 , wherein the polypeptide sequence of the mutant DNA polymerase comprises SEQ ID NO:3 with the exception of comprising SEQ ID NO:12 and having glutamate at amino acid position 355.

6. The mutant DNA polymerase of claim 1 , further comprising an exogenous label.

7. A ternary complex, comprising the mutant DNA polymerase of claim 1 , a primed template nucleic acid and a next correct nucleotide for the primed template nucleic acid.

8. The ternary complex of claim 7 , wherein the next correct nucleotide comprises an exogenous label.

9. The ternary complex of claim 7 , wherein the mutant DNA polymerase comprises an exogenous label.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 1, 2022
From: OMNIOME, LLC
To: PACIFIC BIOSCIENCES OF CALIFORNIA, INC.
Reel/Frame 059278/0153 →
MERGER Recorded Feb 2, 2022
From: OMNIOME, INC.
To: OMNIOME, LLC
Reel/Frame 058952/0352 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 14, 2020
From: VIJAYAN, KANDASWAMY; IYIDOGAN, PINAR
To: OMNIOME, INC.
Reel/Frame 051506/0609 →
Continuity (4)
Continuation 15581822 · Apr 28, 2017
Provisional Application 62444733 · Jan 10, 2017
Provisional Application 62329489 · Apr 29, 2016
Related Publication 20200199668A1 · Jun 25, 2020